(Jan 07, 2022) Vancouver, Wash.-based Absci Corporation inked a research pact with Merck. Under the deal, Absci will leverage its Bionic Protein non-standard amino acid technology and its artificial intelligence-powered integrated Drug Creation Platform to create enzymes to meet Merck’s biomanufacturing applications. Under the terms of the agreement, Absci is eligible for up to $610 million in upfront
Continue Reading(December 20, 2021) Pfizer is to enter the medical cannabis industry betting on a promising cannabinoid-based bowel disease treatment. Last week, American multinational pharmaceutical and biotechnology corporation Pfizer signed an agreement with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.
Continue ReadingAlpine Immune Sciences and Ireland’s Horizon Therapeutics forged a licensing and collaborative research and development agreement valued at up to $1.5 billion to generate up to four preclinical candidates for autoimmune and inflammatory diseases. Horizon will have exclusive rights to develop and commercialize the candidates from Seattle-based Alpine’s unique discovery platform. Overall, the collaboration and licensing agreement between the two
Continue ReadingCambridge, UK – 23rd November 2021 – LoQus23 Therapeutics Ltd. (‘LoQus23’), a company discovering small molecule therapies that target aberrant DNA mismatch repair (MMR) to treat Huntington’s and other triplet repeat diseases (TRDs), announces the successful closing of its £7 million extended seed round. LoQus23 secured the financing from Novartis Venture Fund (NVF) and its
Continue ReadingBiotech company helps make food and consumer products healthier and more sustainable DUBLIN, November 11, 2021 – Nuritas, a biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides, has closed a $45 million USD Series B funding round. The investment, led by Chicago-based Cleveland Avenue, LLC, includes Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund (ECBF),
Continue ReadingIsomorphic Laboratories, an AI-driven startup owned by Google parent firm Alphabet, announced plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind. In a statement, Founder and Chief Executive Demis Hassabis said Isomorphic Labs’ goal is commercial in nature but is anchored on designing a comprehensive drug discovery process using
Continue ReadingMerck and Synthekine Strike $525 Million Cytokine Therapy Deal (November 1, 2021) | By Vanessa Doctor, RN. Merck is widening its reach into the treatment of autoimmune diseases by investing in Synthekine, a bioresearch company that develops engineered cytokine therapeutics. Under a worldwide collaboration and research agreement, Merck can exclusively take advantage of Synthekine’s surrogate
Continue ReadingToday, Ginkgo Bioworks, a synthetic biology company with a goal of programming microbes as easily as one might programming computers, announced it will go public with a $15 billion pre-money valuation by merging with Soaring Eagle Acquisition, a special purpose acquisition company (SPAC). Ginkgo’s $15 billion pre-money equity valuation is one of the largest SPAC deals in history.
Continue ReadingAgBiome’s Best-in-Class Microbial Platform Delivers Crop Protection Solutions to Feed the Growing Population Responsibly. Research Triangle Park, NC — September 14, 2021 — AgBiome, the leader in developing innovative products from the Earth’s microbial communities, announced it has raised $116 million in an oversubscribed Series D round of funding, co-led by Blue Horizon and Novalis
Continue ReadingLumen Bioscience partnered with Google to use machine learning to advance the development of plant-based biologic drugs. The companies will harness the power of machine learning to increase the scalability of medicines based on spirulina, a type of blue-green algae. Lumen’s approach allows for the “rapid and low-cost mass production of new biologic drugs at
Continue Reading